-
Media Release
Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails
-
Media Release
Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails
-
Media Release
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
-
Media Release
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
-
Media Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
-
Media Release
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
-
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
-
Media Release
Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
-
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media Release
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
-
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients